Dean Capital Investments Management LLC Purchases Shares of 1,552 Icon Plc (ICLR)

Dean Capital Investments Management LLC purchased a new stake in Icon Plc (NASDAQ:ICLR) in the 3rd quarter, Holdings Channel reports. The fund purchased 1,552 shares of the medical research company’s stock, valued at approximately $239,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Massachusetts Financial Services Co. MA raised its holdings in Icon by 12.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock valued at $164,561,000 after acquiring an additional 121,970 shares during the last quarter. Private Advisor Group LLC raised its holdings in Icon by 186.6% in the 2nd quarter. Private Advisor Group LLC now owns 8,404 shares of the medical research company’s stock valued at $1,111,000 after acquiring an additional 5,472 shares during the last quarter. Atria Investments LLC raised its holdings in Icon by 18.5% in the 3rd quarter. Atria Investments LLC now owns 6,556 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 1,024 shares during the last quarter. Dorsey Wright & Associates acquired a new position in Icon in the 3rd quarter valued at $6,644,000. Finally, Envestnet Asset Management Inc. raised its holdings in Icon by 376.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 88,669 shares of the medical research company’s stock valued at $11,751,000 after acquiring an additional 70,064 shares during the last quarter. Institutional investors own 85.09% of the company’s stock.

ICLR has been the subject of several analyst reports. BidaskClub upgraded Icon from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. Evercore ISI upgraded Icon from an “in-line” rating to an “outperform” rating in a report on Friday, October 26th. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $163.00 price objective for the company in a report on Thursday, August 9th. Robert W. Baird upped their price objective on Icon from $154.00 to $157.00 and gave the stock an “outperform” rating in a report on Tuesday, September 11th. Finally, UBS Group assumed coverage on Icon in a report on Tuesday, October 9th. They set a “sell” rating and a $145.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Icon presently has an average rating of “Buy” and a consensus price target of $148.00.

ICLR stock opened at $133.82 on Friday. The firm has a market cap of $6.99 billion, a PE ratio of 24.83, a PEG ratio of 1.86 and a beta of 0.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17. Icon Plc has a 52 week low of $101.22 and a 52 week high of $155.33.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, hitting analysts’ consensus estimates of $1.54. The business had revenue of $655.02 million during the quarter, compared to the consensus estimate of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. On average, analysts forecast that Icon Plc will post 6.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dean Capital Investments Management LLC Purchases Shares of 1,552 Icon Plc (ICLR)” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/11/25/dean-capital-investments-management-llc-purchases-shares-of-1552-icon-plc-iclr.html.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply